RxDoctor Payments Data

Tracy Hollan, APRN

Family · Lexington, KYNPI 1538440227

Payments from drug & device makers

$7,470in general payments, 2019–2025

Across 158 payments — averaging $47.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Atricure, Inc.$2K
  • Merck$359
  • Boston Scientific$295
  • Pfizer$292
  • Novartis$269
  • plus $1K from 15 others

What the payments were for

  • Travel & lodging$3,27744%
  • Food & beverage$4,19356%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,470 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$42,776
Medicare patients
265
Services billed
726

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban73$53,471
JardianceEmpagliflozin43$37,878
EntrestoSacubitril/Valsartan34$28,343
Repatha SureclickEvolocumab18$9,798
Praluent PenAlirocumab11$5,247
Bumetanide100$2,634
Midodrine Hcl12$1,681
Potassium Chloride118$1,435
Flecainide Acetate11$1,429
Metoprolol Succinate100$857
Spironolactone83$605
Losartan Potassium65$490
Furosemide118$372
Amlodipine Besylate58$339
Nitroglycerin17$292

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$292$53,47173 claims
Boehringer IngelheimJardiance$229$37,87843 claims
NovartisEntresto$269$28,34334 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.

Other family in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →